Pharmaceutical Executive

In this Q&A, Craig Serra, head of commercial solutions and partnerships within the clinical research business unit at Flatiron Health (affiliate of the Roche Group), shares his perspective on clinical research, the role of data, and Flatiron Health’s efforts to that end.

Join Pharmaceutical Executive® for an information-packed virtual conference that provides valuable advice to bolster and transform the way you reach HCPs in this time of evolution. Live: Thursday, Aug. 13, 2020 at 8:15AM EDT. On demand available after airing until Aug. 13, 2021.

ZS offers advice to ensure reps can stay engaged with their customers during these times of changing needs and constraints.

Banks Bourne of Tanner Pharma Group talks about the organization's role in delivering access initiatives for products not commercially available in many parts of the world.

Natalie Douglas talks about her experience in the area of managed and expanded access and her new venture, RareiTi.

Rick Krohn talks to Pharm Exec about the pharma applications of one of tech’s hottest solutions – blockchain.

Tommy Bramley and Kristine Flemister discuss today’s increasingly complex healthcare environment, and share insights into how stakeholders should be evolving to better help patients and providers navigate barriers around access and affordability.

At recent the BETHEEXPERT 2017 event in Budapest, we asked Romuald Braun what pharma should be focusing on with regard to its labeling activities.

Pharm Exec speaks to Andrew Marr about the implications of the European Union's new IDMP (Identification of Medicinal Products) regulations for the pharma industry.

The digital workplace is defined as a “business strategy to boost employee engagement and agility through a more consumerized work environment”. But what exactly does this mean for life sciences organizations? Michael Woodbridge explains.

Industry investment in pharma sales force and marketing channels remained “flat” in 2013 at just under €85 billion constant US dollars.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) yesterday launched what it called “a landmark paper” outlining steps towards an integrated strategy for the life sciences sector in Europe.

Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report.

Eli Lilly and Company has announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com.

Vietnam’s pharma market in Vietnam is set to increase by $5 billion over the next six years.

Turkey is remains a key destination for foreign investment, and the next five years should see renewed interest from pharma multinationals, says a new report by CPhI Worldwide.

While some clinical trial sponsors have been driven out of the BRIC nations.

Despite Mexico’s efforts to improve its regulatory framework and create a better business environment for pharma.

Novartis has teamed with the French drug maker Servier to develop and commercialize novel drug candidates targeting apoptosis in oncology.

Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.

Gilead’s hepatitis C treatment Sovaldi will top the list of biggest selling drugs in 2020, according to UK market intelligence company, Evaluate.

The pancreatic cancer market is set to climb from $855.8 million in 2012 to approximately $1.21 billion by 2019 (a CAGR of 5.1%), says a report from GBI Research.

The European Parliament yesterday voted towards the adoption of the new Clinical Trials Regulation.

The global pancreatic cancer treatment market value in the six major countries (U.S., France, Germany, Italy, Spain and the UK) will increase from $529 million in 2012 to $1.63 billion by 2017.

Baxter International plans to create two separate, independent global healthcare companies, with one focused on biopharmaceuticals and the other on medical products.